 that it has signed an agreement with German-based biopharma manufacturer Rentschler Biotechnologie GmbH for the development of PBD-C06, a pGlu-Abeta-specific monoclonal antibody, as treatment for patients with Alzheimer’s disease.

	The contract comprises all stages of production and processing from initial cell-line development through to the manufacturing of material for preclinical and clinical studies. Rentschler is an independent contract manufacturer with experience in producing biopharmaceuticals for more than 40 years.

	PBD-C06 is a chimeric, de-immunized monoclonal antibody selected as a candidate with the best safety, efficacy, and pharmacological profile from among several pre-clinical candidates. It targets pGlu-Abeta, aiming to selectively clear the brain of pGlu-Abeta while leaving non-toxic forms of Abeta untouched. In Alzheimer’s disease animal models, PBD-C06 reduced pGlu-Abeta and total Abeta levels and positively affected memory function. 

	To date Probiodrug has progressed two complementary strategies for tackling pGlu-Abeta, with two medicine candidates in development-PQ912, a small molecule inhibitor of Glutaminyl Cyclase, in phase 2, and PBD-C06, a pGlu-Abeta-specific mAB in preclinical stage.

Biopharma News

Manufacturing

Manufacturing, Biologics

Manufacturing, Cell-Line Selection

News

Upstream Processing

Probiodrug has signed an agreement with Rentschler Biotechnologie GmbH for the development of PBD-C06, a pGlu-Abeta-specific monoclonal antibody, as treatment for patients with Alzheimer’s disease.